From “ACAN” to “I CAN”: Restoring wellness in a boy with severe osteochondritis dissecans through diagnostic precision combined with optimal medical, surgical and rehabilitation management
暂无分享,去创建一个
A. Innes | F. Rauch | J. Lazier | S. Carsen | K. Koujok | L. Ward | N. Shenouda | Jonathan M Dawrant | M. Robinson | M. Pagé | M. Ochoa | Ashlee Yang | C. Kollias | Christina Bakir | Joanna Lazier
[1] Jeffery A Taylor-Haas,et al. Clinical phenotype and musculoskeletal characteristics of patients with aggrecan deficiency , 2022, American journal of medical genetics. Part A.
[2] V. Hwa,et al. Treatment of Short Stature in Aggrecan Deficient Patients with Recombinant Human Growth Hormone: One-Year Response. , 2021, The Journal of clinical endocrinology and metabolism.
[3] Philippe M. Campeau,et al. Variable expressivity in a family with an aggrecanopathy , 2021, Molecular genetics & genomic medicine.
[4] I. Rabbone,et al. Retrospective Diagnosis of a Novel ACAN Pathogenic Variant in a Family With Short Stature: A Case Report and Review of the Literature , 2021, Frontiers in Genetics.
[5] D. Umebayashi,et al. Symptomatic Chiari type 1 malformation associated with acromegaly: A case report , 2021, Surgical neurology international.
[6] D. Rosenzweig,et al. The Link between Aggrecan and Familial Osteochondritis Dissecans , 2021, Surgeries.
[7] Guramrit Singh,et al. The Branched Nature of the Nonsense-Mediated mRNA Decay Pathway. , 2020, Trends in genetics : TIG.
[8] R. Elwy,et al. Effects of growth hormone therapy in pediatric patients with growth hormone deficiency and Chiari I malformation: a retrospective study , 2019, Child's Nervous System.
[9] A. Kothari,et al. Juvenile osteochondritis dissecans (JOCD) of the knee: current concepts review , 2019, EFORT open reviews.
[10] S. Zaffagnini,et al. Osteochondritis Dissecans of the Knee: Etiology and Pathogenetic Mechanisms. A Systematic Review , 2018, Cartilage.
[11] D. Larson,et al. Incidence of symptomatic osteochondritis dissecans lesions of the knee: a population-based study in Olmsted County. , 2017, Osteoarthritis and cartilage.
[12] S. Lalani,et al. Clinical Characterization of Patients With Autosomal Dominant Short Stature due to Aggrecan Mutations , 2017, The Journal of clinical endocrinology and metabolism.
[13] Laura A. Treadgold,et al. Amalgamated Reference Data for Size‐Adjusted Bone Densitometry Measurements in 3598 Children and Young Adults—the ALPHABET Study , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[15] Luca Monti,et al. Alteration of proteoglycan sulfation affects bone growth and remodeling , 2013, Bone.
[16] M. O’Grady,et al. Symptomatic Chiari 1 malformation after initiation of growth hormone therapy. , 2011, The Journal of pediatrics.
[17] Takako Sasaki,et al. A missense mutation in the aggrecan C-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans. , 2010, American journal of human genetics.
[18] R. Davey,et al. Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis. , 2005, Health Technology Assessment.
[19] C. Little,et al. Mechanisms involved in cartilage proteoglycan catabolism. , 2000, Matrix biology : journal of the International Society for Matrix Biology.
[20] E. Rappaport,et al. Effects of exogenous growth hormone on growth plate cartilage in rats. , 1987, A M A Journal of Diseases of Children.